Teva Pharmaceutical Industries Limited (TEVA) Stock Price
TEVAStock
$41.50+11.38%52W
Market Cap$48.40B
P/E34.31x
PEG Ratio0.71
Div yield—
Beta0.45
TEVA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)26.61%
Price vs S&P 500 (4W)10.80%
PEG Ratio0.71
VGM Score58.00
P/E Ratio (Annual)34.31x
TEVA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.11 | $0.02 | -81.46%(-$0.09) | |
| Q1 2026 | $0.46 | $0.53 | +16.23%(+$0.07) | |
| Q4 2025 | $0.64 | $0.96 | +50.17%(+$0.32) | |
| Q3 2025 | $0.67 | $0.78 | +15.74%(+$0.11) | |
| Q2 2025 | $0.62 | $0.66 | +7.31%(+$0.04) |
TEVA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TEVATeva Pharmaceutical Industries Limited | D | C | A | 2.8x | 4.1% | 52.9% | — | $41.50 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Teva Pharmaceutical Industries Limited
Teva is the world's leading generic pharmaceutical manufacturer, with approximately half its revenue derived from North America where it captures a high single-digit percentage of US generic prescriptions. Beyond generics, the Israel-based company operates a specialty portfolio including innovative medicines and biosimilars across central nervous system, respiratory, and oncology therapeutic areas. Teva also generates revenue through active pharmaceutical ingredients, contract manufacturing, and Anda, its US-based generic and specialty drug distributor.